Anti–PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in MiceSummary

Background & Aims: Intrahepatic cholangiocarcinoma (iCCA) accounts for a fraction of primary liver cancers but has a 5-year survival rate of only 10%. Immune checkpoint inhibitors are effective in treating many solid cancers, but immune checkpoint inhibitor monotherapy has no clear benefit in iC...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Simon Wabitsch, Mayank Tandon, Benjamin Ruf, Qianfei Zhang, Justin D. McCallen, John C. McVey, Chi Ma, Benjamin L. Green, Laurence P. Diggs, Bernd Heinrich, Tim F. Greten
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Elsevier 2021-01-01
Ráidu:	Cellular and Molecular Gastroenterology and Hepatology
Fáttát:	Intrahepatic Cholangiocarcinoma Anti–PD-1 Monoclonal Antibody Trametinib
Liŋkkat:	http://www.sciencedirect.com/science/article/pii/S2352345X21001004
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!